These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 26878908)
1. Regulatory role of hexosamine biosynthetic pathway on hepatic cancer stem cell marker CD133 under low glucose conditions. Lin SH; Liu T; Ming X; Tang Z; Fu L; Schmitt-Kopplin P; Kanawati B; Guan XY; Cai Z Sci Rep; 2016 Feb; 6():21184. PubMed ID: 26878908 [TBL] [Abstract][Full Text] [Related]
2. Active glycolytic metabolism in CD133(+) hepatocellular cancer stem cells: regulation by MIR-122. Song K; Kwon H; Han C; Zhang J; Dash S; Lim K; Wu T Oncotarget; 2015 Dec; 6(38):40822-35. PubMed ID: 26506419 [TBL] [Abstract][Full Text] [Related]
3. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway. Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741 [TBL] [Abstract][Full Text] [Related]
4. Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells. Song Y; Jang J; Shin TH; Bae SM; Kim JS; Kim KM; Myung SJ; Choi EK; Seo HR J Exp Clin Cancer Res; 2017 Mar; 36(1):38. PubMed ID: 28253902 [TBL] [Abstract][Full Text] [Related]
5. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174 [TBL] [Abstract][Full Text] [Related]
6. Hyaluronan Production Regulates Metabolic and Cancer Stem-like Properties of Breast Cancer Cells via Hexosamine Biosynthetic Pathway-coupled HIF-1 Signaling. Chanmee T; Ontong P; Izumikawa T; Higashide M; Mochizuki N; Chokchaitaweesuk C; Khansai M; Nakajima K; Kakizaki I; Kongtawelert P; Taniguchi N; Itano N J Biol Chem; 2016 Nov; 291(46):24105-24120. PubMed ID: 27758869 [TBL] [Abstract][Full Text] [Related]
7. Oxytetracycline have the therapeutic efficiency in CD133 Song Y; Kim IK; Choi I; Kim SH; Seo HR Sci Rep; 2018 Oct; 8(1):16100. PubMed ID: 30382122 [TBL] [Abstract][Full Text] [Related]
8. CXCL3 contributes to CD133(+) CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation. Zhang L; Zhang L; Li H; Ge C; Zhao F; Tian H; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J Sci Rep; 2016 Jun; 6():27426. PubMed ID: 27255419 [TBL] [Abstract][Full Text] [Related]
9. Role of ADAM17 in invasion and migration of CD133-expressing liver cancer stem cells after irradiation. Hong SW; Hur W; Choi JE; Kim JH; Hwang D; Yoon SK Oncotarget; 2016 Apr; 7(17):23482-97. PubMed ID: 26993601 [TBL] [Abstract][Full Text] [Related]
10. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269 [TBL] [Abstract][Full Text] [Related]
11. CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma. Jang JW; Song Y; Kim SH; Kim JS; Kim KM; Choi EK; Kim J; Seo HR Cancer Lett; 2017 Mar; 389():1-10. PubMed ID: 28034805 [TBL] [Abstract][Full Text] [Related]
12. CD133 Liu K; Hao M; Ouyang Y; Zheng J; Chen D Sci Rep; 2017 Jan; 7():41499. PubMed ID: 28134312 [TBL] [Abstract][Full Text] [Related]
14. ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1α. Lee JH; Hur W; Hong SW; Kim JH; Kim SM; Lee EB; Yoon SK Oncol Rep; 2017 Feb; 37(2):813-822. PubMed ID: 27959451 [TBL] [Abstract][Full Text] [Related]
15. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564 [TBL] [Abstract][Full Text] [Related]
16. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma. Pham LV; Bryant JL; Mendez R; Chen J; Tamayo AT; Xu-Monette ZY; Young KH; Manyam GC; Yang D; Medeiros LJ; Ford RJ Oncotarget; 2016 Dec; 7(49):80599-80611. PubMed ID: 27716624 [TBL] [Abstract][Full Text] [Related]
17. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma. Zhang L; Sun H; Zhao F; Lu P; Ge C; Li H; Hou H; Yan M; Chen T; Jiang G; Xie H; Cui Y; Huang X; Fan J; Yao M; Li J Cancer Res; 2012 Aug; 72(16):4276-85. PubMed ID: 22773665 [TBL] [Abstract][Full Text] [Related]
18. Eukaryotic Initiation Factor 5A2 Contributes to the Maintenance of CD133(+) Hepatocellular Carcinoma Cells via the c-Myc/microRNA-29b Axis. Bai HY; Liao YJ; Cai MY; Ma NF; Zhang Q; Chen JW; Zhang JX; Wang FW; Wang CY; Chen WH; Jin XH; Xu RH; Guan XY; Xie D Stem Cells; 2018 Feb; 36(2):180-191. PubMed ID: 29119708 [TBL] [Abstract][Full Text] [Related]
19. iNOS promotes CD24 Wang R; Li Y; Tsung A; Huang H; Du Q; Yang M; Deng M; Xiong S; Wang X; Zhang L; Geller DA; Cheng B; Billiar TR Proc Natl Acad Sci U S A; 2018 Oct; 115(43):E10127-E10136. PubMed ID: 30297396 [TBL] [Abstract][Full Text] [Related]
20. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Zhu Z; Hao X; Yan M; Yao M; Ge C; Gu J; Li J Int J Cancer; 2010 May; 126(9):2067-78. PubMed ID: 19711346 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]